For research use only. Not for therapeutic Use.
Gepotidacin（Cat No.:I006951）is a novel, broad-spectrum antibiotic developed for the treatment of bacterial infections, particularly in Gram-positive and Gram-negative bacteria. As a member of the novel triazolopiperazine class, it works by inhibiting bacterial type II topoisomerases, which are essential for DNA replication and cell division. Gepotidacin is effective against a range of pathogens, including Streptococcus pneumoniae, Escherichia coli, and Neisseria gonorrhoeae, and has shown promising results in treating urinary tract infections and gonorrhea. Its unique mechanism offers a potential solution to multi-drug resistant infections.
| Catalog Number | I006951 |
| CAS Number | 1075236-89-3 |
| Synonyms | GSK-2140944; GSK2140944; GSK 2140944; GSK-2140944E; GSK2140944E; GSK 2140944E; Gepotidacin;(2R)-2-[(4-{[(3,4-dihydro-2H-pyrano[2,3-c]pyridin- 6-yl)methyl]amino}piperidin-1-yl)methyl]-1,2-dihydro- 3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione |
| Molecular Formula | C24H28N6O3 |
| Purity | ≥95% |
| Target | topoisomerase inhibitor |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | (3R)-3-[[4-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione |
| InChI | InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2/t19-/m1/s1 |
| InChIKey | PZFAZQUREQIODZ-LJQANCHMSA-N |
| SMILES | C1CC2=CC(=NC=C2OC1)CNC3CCN(CC3)C[C@@H]4CN5C(=O)C=CC6=C5N4C(=O)C=N6 |
| Reference | </br>1:Gepotidacin (GSK2140944) <i>In Vitro</i> Activity against Gram-positive and Gram-negative Bacteria (MBC/MIC, Kill Kinetics, Checkerboard, PAE/SME tests). Flamm RK, Farrell DJ, Rhomberg PR, Scangarella-Oman NE, Sader HS.Antimicrob Agents Chemother. 2017 May 8. pii: AAC.00468-17. doi: 10.1128/AAC.00468-17. [Epub ahead of print] PMID: 28483959 </br>2:The Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections. O/’Riordan W, Tiffany C, Scangarella-Oman N, Perry C, Hossain M, Ashton T, Dumont E.Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.02095-16. doi: 10.1128/AAC.02095-16. [Epub ahead of print] PMID: 28373199 Free Article</br>3:Analysis of MIC and disk diffusion testing variables for gepotidacin and comparator agents against select bacterial pathogens. Koeth LK, DiFranco-Fisher JM, Scangarella-Oman NE, Miller LA.J Clin Microbiol. 2017 Mar 22. pii: JCM.02366-16. doi: 10.1128/JCM.02366-16. [Epub ahead of print] PMID: 28330893 </br>4:A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers. Hossain M, Zhou M, Tiffany C, Dumont E, Darpo B.Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02385-16. doi: 10.1128/AAC.02385-16. Print 2017 May. PMID: 28223381 Free PMC Article</br>5:<i>In Vitro</i> Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae. Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK.Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02047-16. doi: 10.1128/AAC.02047-16. Print 2017 Mar. PMID: 28069643 </br>6:Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models. Bulik CC, Okusanya ÓO, Lakota EA, Forrest A, Bhavnani SM, Hoover JL, Andes DR, Ambrose PG.Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e00115-16. doi: 10.1128/AAC.00115-16. Print 2017 Feb. PMID: 27872075 </br>7:Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226. Jones RN, Fedler KA, Scangarella-Oman NE, Ross JE, Flamm RK.Antimicrob Agents Chemother. 2016 Jun 20;60(7):4404-6. doi: 10.1128/AAC.00527-16. Print 2016 Jul. PMID: 27161642 Free PMC Article</br>8:In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens. Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF.Antimicrob Agents Chemother. 2016 Jan 4;60(3):1918-23. doi: 10.1128/AAC.02820-15. PMID: 26729499 Free PMC Article |
